Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Results clear on some things, not on others..I’m not a Dr.
View:
Post by canadafan on May 25, 2023 5:31pm

Results clear on some things, not on others..I’m not a Dr.

The results do show a clear improvement Pala + pactataxil alone.
cohort 2 vs #1.
beyond that. I'm not qualified to determine if this is over the top good or not.
No N.R., puzzles me.
Well tomorrow is yet another day....
The ambiguity does explain why a verbal communication & KOL followup is required.
Certainly not bad news.
The triplet combo, did not improve at all.
Comment by Quentin30 on May 25, 2023 5:41pm
You said it Canada... more ambiguity... Have ONCY ever run a trial that proves beyond a shadow of a doubt that Pela works..?? The IND was only powered to 90%, meaning there was a 10% chance the data were a fluke... oh well, nothing to see until Q1 24 when the OS data is out.. GLTA
Comment by Azzak34 on May 25, 2023 5:49pm
Hahaha what a tool! The numbers aren't even up to date and rheyre great. That's human beings still alive you parasite. 
Comment by fox7mf on May 25, 2023 5:44pm
+50% improvement in ORR & PFS...very very good.
Comment by Noteable on May 25, 2023 5:51pm
The "triplet therapy" (Cohort 3) involving the addition of an immune checkpoint inhibitor resulted in a 70.6% disease control rate at 16 weeks versus a 46.7% control rate for the placebo of paclitaxel alone (Cohort 1). And this result occured in a heavily pre-treated group of metastatic breast cancer patients.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities